IPH5201

Monalizumab progressing to Phase 3 PACIFIC-9 lung cancer clinical trial in partnership with AstraZeneca First CD123 tri-specific ANKET TM starts Phase 1 study by Sanofi Lacutamab encouraging MF data...

Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca’s randomized Phase 2 COAST study in unresectable, Stage III NSCLC, advancing to Phase 3 Pre-clinical...

• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma • Company’s...

Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic Innate Pharma SA (Euronext...

Cash, cash equivalents and financial assets of the Company amounted to €215.2 million* $79.1 million (€71.4 million**) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to...

Preclinical data showcases advancement of its immuno-oncology portfolio across the Company’s three strategic pillars: immune checkpoint inhibitors, tumor antigen targeting and tumor micro-environment...

The production of adenosine via CD39 and CD73 enzymes participates in an immunosuppressive tumor microenvironment. Perrot et al. generated two antibodies, IPH5201 and IPH5301, targeting human CD39 and...

New preclinical data highlights IPH5201 (anti-CD39) and IHP5301 (anti-CD73) neutralizing antibodies targeting the immunosuppressive adenosine pathway First data presented from Innate Pharma’s...

Innate Pharma acquires US and EU rights to commercialize Lumoxiti to become a fully-integrated oncology-focused biotech AstraZeneca obtains full oncology rights to monalizumab AstraZeneca gains access...

Next generation of immunotherapies presented by Chief Scientific Officer Eric Vivier in a meet-the-expert session at AACR 2018 New preclinical data further support ongoing clinical trials with...